Previous 10 | Next 10 |
TherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing. TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction...
Citing the ongoing supply issues affecting a key product, H.C. Wainwright has trimmed the price target of the women’s healthcare company, TherapeuticsMD (TXMD -3.1%) on Friday. After reporting worse-than-expected financials for Q4 2021, TherapeuticsMD (NASDAQ:TXMD) shares crashed ...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q4 2021 Earnings Call Mar 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript
TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Conference Call March 10, 2022, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Hugh O’Dowd - Chief Executive Officer James D’Arecca - Chief Financial Officer Mark Glickman - Chief Business Officer Conference Call Pa...
The shares of TherapeuticsMD (TXMD -20.2%) are trading sharply lower in morning hours after the women’s healthcare company reported lower than expected financials for Q4 2021. Revenue for the quarter at $18.7M missed average estimates of analysts by as much as $10.7M after a decli...
Therapeutics MD press release (NASDAQ:TXMD): Q4 GAAP EPS of -$0.10 misses by $0.02. Revenue of $18.67M (-17.4% Y/Y) misses by $10.72M. As of December 31, 2021, the Company’s cash on hand totaled $65.1 million, compared with $80.5 million as of December 31, 2020. Shares -2.88% PM. For...
- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women’s healthcare - - Amended credit terms with Sixth Street in support of a new capitalization plan - - Conference call scheduled for 8:30 a.m. E...
Therapeutics MD (NASDAQ:TXMD) is scheduled to announce Q4 earnings results on Thursday, March 10th, before market open. The consensus EPS Estimate is -$0.08 and the consensus Revenue Estimate is $29.39M (+30.0% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of the time and has ...
Buying Penny Stocks Today? Here’s What You Need to Know With another potentially volatile day of trading for penny stocks and blue chips, there is a lot for investors to consider. As we all know, the largest contributing factor to stock market movement right now is the war going ...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...